JenaValve wins FDA approval for Trilogy valve in severe AR

CURRENT BRIEF VERSION: JenaValve’s Trilogy Transcatheter Heart Valve System has won FDA premarket approval for treating symptomatic, severe native aortic valve regurgitation in patients considered at high or greater risk for surgical aortic valve replacement. The approval, dated March 17, 2026, gives clinicians the first FDA-approved transcatheter aortic valve replacement option specifically for this group, a population that has historically had limited alternatives beyond surgery or conservative medical management. FDA’s indication is limited to native tricuspid aortic valve regurgitation and excludes cases tied to acute endocarditis, rheumatic heart disease, or acute aortic dissection. JenaValve has said it plans an immediate launch through participating study sites, followed by broader rollout to hospitals across the US. (accessdata.fda.gov; PharmaShots)

Why it matters: For veterinary professionals tracking cardiovascular innovation, this is another example of device makers winning narrower, evidence-backed labels for patients who have fallen outside standard transcatheter valve indications. The approval was supported by the ALIGN-AR pivotal study, which showed 6.2% all-cause mortality at one year in the premarket cohort, 95.0% technical success, and a 24.0% new permanent pacemaker rate among patients without prior pacemakers at 30 days. Trilogy was built for anatomy that has challenged conventional TAVR systems: it uses radiopaque locators to attach directly to native aortic leaflets without depending on calcification for anchoring, a design intended to support stable implantation, precise alignment, and less paravalvular regurgitation while preserving future coronary access through an open-cell nitinol frame. That benefit-risk profile suggests meaningful progress, but also highlights the procedural complexity and conduction-related tradeoffs that still shape adoption of structural heart devices. (accessdata.fda.gov; PharmaShots)

What to watch: FDA has already posted two post-approval study tracks, including continued follow-up of the premarket cohort and registry-based real-world surveillance, so the next phase will be longer-term durability and safety data in broader clinical use. Uptake will also depend on how quickly the company’s study-site launch expands into routine hospital use. (accessdata.fda.gov; PharmaShots)